Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Biogen

Pharmaceutical intelligence for Biogen with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 3
Assets: 3

Recent signals(2)

ClinicalJune 18, 2026

Biogen's Felzartamab Study Targets Immunoglobulin A Nephropathy in Adults

A clinical trial is underway to evaluate the effects of felzartamab on proteinuria in adults with IgAN.

ClinicalJune 17, 2026

Analysis Reveals Key Trends in ALS Immunotherapeutics Research and Collaboration Gaps

The bibliometric analysis highlights a significant increase in ALS immunotherapeutics research, with a shift towards advanced immunomodulatory strategies and regulatory T cell modulation.

Upcoming catalysts(1)

FDA Approval

Biogen — Leqembi

Subcutaneous formulation approval could expand addressable patient pool and access.

August 1, 2026 · NDA/BLA

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(2)

ClinicalJune 18, 2026

Biogen's Felzartamab Study Targets Immunoglobulin A Nephropathy in Adults

A clinical trial is underway to evaluate the effects of felzartamab on proteinuria in adults with IgAN.

ClinicalJune 17, 2026

Analysis Reveals Key Trends in ALS Immunotherapeutics Research and Collaboration Gaps

The bibliometric analysis highlights a significant increase in ALS immunotherapeutics research, with a shift towards advanced immunomodulatory strategies and regulatory T cell modulation.

Competitive activity

No signals indexed for this entity yet.

Assets

Felzartamab →

Therapeutic areas

Amyotrophic Lateral Sclerosis →

Immunoglobulin A Nephropathy →

Nephrology · Immunoglobulin A Nephropathy →

Neurology · Amyotrophic Lateral Sclerosis →

Indications

Alzheimer's disease (subcutaneous) →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.